# Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy

> **NCT05383716** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 80 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Neoadjuvant Therapy
- Immune Checkpoint Inhibitor

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05383716
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2023-12-08
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383716, "Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05383716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*